NCT00381550View on ClinicalTrials.gov

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Accelerated Phase Chronic Myelogenous LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic Phase Chronic Myelogenous LeukemiaChronic Eosinophilic LeukemiaChronic Myelomonocytic LeukemiaEssential ThrombocythemiaPhiladelphia Chromosome Negative Chronic Myelogenous LeukemiaPolycythemia VeraPrimary MyelofibrosisRelapsing Chronic Myelogenous Leukemia
Interventions
DRUG

fludarabine phosphate

Given IV

DRUG

triapine

Given IV

PROCEDURE

laboratory biomarker analysis

Correlative study

Trial Locations (1)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00381550 - 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter